Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT-527 Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AT-527 Formulation 1 Dose 1 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 1 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 2 | EXPERIMENTAL | - |
| AT-527 Formulation 1 Dose 3 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 3 | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 1 Fast/Fed | EXPERIMENTAL | - |
| AT-527 Formulation 2 Dose 3 Fast/Fed | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AT-527 Formulation 1 | DRUG | AT-527 Formulation 1 (R07496998) |
| Placebo Comparator | OTHER | Placebo Comparator |
| AT-527 Formulation 2 | DRUG | AT-527 Formulation 2 (R07496998) |
Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg...
AT-527 Formulation 1 is a small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial that enrolled 81 participants in Canada. The study was randomized, double-blind, and controlled, evaluating the drug in healthy subjects aged 18 years and older.
AT-527 Formulation 1 is being developed by Atea Pharmaceuticals, Inc., which trades under the ticker AVIR. The company is conducting clinical research on this small molecule, with the current Phase 1 study completed. The trial was conducted in Canada with 81 healthy volunteers.
AT-527 Formulation 1 is in Phase 1 clinical development. The single trial, NCT04711187, has been completed. This Phase 1 study was a randomized, double-blind, controlled trial involving 81 healthy volunteers in Canada. The drug is investigational and not yet approved for any use.
AT-527 Formulation 1 has one completed Phase 1 clinical trial, identified as NCT04711187, titled 'Study of AT-527 in Healthy Subjects (R07496998)'. This trial enrolled 81 healthy volunteers in Canada, with participants aged 18 years and older. The study was randomized, double-blind, and controlled.
AT-527 Formulation 1 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only trial, NCT04711187, has been completed and involved healthy volunteers. The drug has not yet progressed to later-stage trials or received regulatory approval.